Summary & Overview
HCPCS G9838: Patient Has Metastatic Disease at Diagnosis
HCPCS Level II code G9838 designates that a patient has metastatic disease identified at the time of initial cancer diagnosis. Nationally, clear documentation of metastatic status at diagnosis is critical for accurate staging, treatment planning, quality measurement, and claims processing across oncology care settings. Use of G9838 supports consistent capture of advanced disease status, which affects clinical decision-making and downstream utilization patterns.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code’s clinical intent and typical settings of use, plus what to expect in benchmarking and policy context. The publication covers common billing and documentation considerations, national benchmarks where available, and recent policy or coding guidance that may affect claim adjudication and quality reporting.
This summary is written for a national audience and focuses on clinical and billing implications rather than state-specific rules. Data not available in the input will be noted where applicable.
Billing Code Overview
HCPCS Level II code G9838 indicates that the patient has metastatic disease at diagnosis. This code is used to document the presence of metastases identified at the time of initial cancer diagnosis.
-
Service type: Diagnostic status documentation related to oncology care
-
Typical site of service: Oncology clinics, hospital outpatient departments, and other settings where initial cancer staging and diagnostic documentation occur
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult newly diagnosed with a primary malignancy and documented distant metastatic disease at initial presentation. The patient presents to an oncology clinic or hospital outpatient department for staging discussion, treatment planning, and initiation of systemic therapy. The clinical workflow includes review of pathology and imaging confirming metastases (e.g., liver, lung, bone), documentation of metastatic disease in the medical record, performance of baseline labs and performance status assessment, multidisciplinary tumor board review when indicated, and initiation of chemotherapy, targeted therapy, immunotherapy, palliative radiation, or referral to hospice depending on goals of care. Typical sites of service include outpatient oncology clinics, hospital outpatient departments, and inpatient oncology wards when admission is required for symptom control or initiation of therapy.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services | When work substantially exceeds usual for documentation or complexity related to metastatic disease complexity (subject to payer review). |
23 | Unusual anesthesia |